Gyre Therapeutics (Gyre Therapeutics) Cash-to-Debt : 81.93 (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Gyre Therapeutics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Gyre Therapeutics's cash to debt ratio for the quarter that ended in Dec. 2023 was 81.93.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Gyre Therapeutics could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Gyre Therapeutics's Cash-to-Debt or its related term are showing as below:

GYRE' s Cash-to-Debt Range Over the Past 10 Years
Min: 21.54 Med: 41.07 Max: 81.93
Current: 81.93

During the past 3 years, Gyre Therapeutics's highest Cash to Debt Ratio was 81.93. The lowest was 21.54. And the median was 41.07.

GYRE's Cash-to-Debt is ranked better than
76.93% of 1539 companies
in the Biotechnology industry
Industry Median: 6.51 vs GYRE: 81.93

Gyre Therapeutics Cash-to-Debt Historical Data

The historical data trend for Gyre Therapeutics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Gyre Therapeutics Cash-to-Debt Chart

Gyre Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Cash-to-Debt

21.54

41.07

81.93

Gyre Therapeutics Semi-Annual Data
	Dec21	Dec22	Dec23
Cash-to-Debt	21.54	41.07	81.93

Competitive Comparison of Gyre Therapeutics's Cash-to-Debt

For the Biotechnology subindustry, Gyre Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Gyre Therapeutics's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gyre Therapeutics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Gyre Therapeutics's Cash-to-Debt falls into.

Gyre Therapeutics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Gyre Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	33.509	/	(0.21	+	0.199)
	=	81.93

Gyre Therapeutics's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	33.509	/	(0.21	+	0.199)
	=	81.93

Gyre Therapeutics (NAS:GYRE) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Gyre Therapeutics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Gyre Therapeutics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Gyre Therapeutics (Gyre Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gyre Therapeutics Inc (NAS:GYRE) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

L9S:Germany

Address

12770 High Bluff Drive, Suite 150, San Diego, CA, USA, 92130

Website

https://www.gyretx.com

Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.

Gyre Therapeutics (Gyre Therapeutics) Headlines

From GuruFocus

Totus Medicines Announces Appointment of Nassim Usman, Ph.D., as President & CEO and the Closing of a $66M Series B Funding

By PRNewswire • 12-15-2023